SECONDARY DISSEMINATED BREAST CANCER IN A REPRODUCTIVE-AGE WOMAN (CLINICAL CASE)
Main Article Content
Abstract
Locally advanced breast cancer (LBC) is defined as breast cancer with one of the following features: tumor spread to the skin of the breast, tumor spread to the underlying chest wall, metastases in the ipsilateral supraclavicular lymph nodes, metastases in the ipsilateral subclavian lymph nodes, ipsilateral axillary metastases that are adherent or fixed to other structures, or a large tumor in a small breast. This definition of locally advanced breast cancer includes stage IIIa, stage IIIb, stage IIIc, and partially stage IIb according to the latest TNM classification.
Every year, 300000-350000 new cases of locally advanced breast cancer are diagnosed worldwide. The most common symptom of locally advanced breast cancer is skin swelling. Most patients with edematous-infiltrative locally advanced breast cancer have palpable axillary lymph nodes, and 30% – distant metastases. Three-year overall survival for women with stage IIIB disease is 41.3%, with stage IV – 12.5% (p = 0.006), which indicates the need for early diagnosis. Despite multimodal treatment, the prognosis of this disease remains unfavorable, and three-year survival does not exceed 30-40%.
The presented article describes a clinical case of edematous-infiltrative form of secondary locally advanced breast cancer.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, et al. NCCN Guidelines Insights: Older Adult Oncology, Version 1.2021. J Natl Compr Canc Netw. 2021; 19(9): 1006-1019. doi: 10.6004/jnccn.2021.0043
Wang GL, Tsikouras P, Zuo HQ, Huang MQ, Peng L, Bothou A, et al. Radioactive seed localization and wire guided localization in breast cancer: A systematic review and meta-analysis. J BUON. 2019; 24(1): 48-60
Fares J, Kanojia D, Rashidi A, Ahmed AU, Balyasnikova IV, Lesniak MS. Diagnostic Clinical Trials in Breast Cancer Brain Metastases: Barriers and Innovations. Clin Breast Cancer. 2019; 19(6): 383-391. doi: 10.1016/j.clbc.2019.05.018
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020; 31(12): 1623-1649. doi: 10.1016/j.annonc.2020.09.010
The stаte of oncologicаl cаre to the populаtion of Russiа in 2021. Ed. by АD Kаprin, VV Stаrinskiy, АO Shаkhzаdovа. M.: P. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia, 2022. 239 p. Russian (Состояние онкологической помощи населению России в 2021 году /под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.)
Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019; 30(4): 558-566. doi: 10.1093/annonc/mdz012
Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC, et al. Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial. JAMA Oncol. 2019; 5(5): e190339-e190339. doi: 10.1001/jamaoncol.2019.0339
du Rusquec P, Blonz C, Frenel JS, Campone M. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. Ther Adv Med Oncol. 2020; 12: 1758835920940939. doi: 10.1177/1758835920940939
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020; 18(4), 452-478. doi: 10.6004/jnccn.2020.0016
Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, et al. Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020; 38(3): 203-213. doi: 10.1200/JCO.20.00164
Suleman K, Almalik O, Haque E, Mushtaq A, Badran A, Alsayed A, et al. Does the Timing of Surgery after Neoadjuvant Therapy in Breast Cancer Patients Affect the Outcome? Oncology. 2020; 98(3): 168-173. doi: 10.1159/000504964
Slamon DJ, Neven P, Chia S., Fasching PA, De Laurentiis М, Im SA, et. al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. Ann Oncol. 2020; 382(6): 514-524. doi: 10.1016/j.annonc.2020.09.010
Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019; 5(1): 5. doi: 10.1038/s41523-018-0097-z